Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert
Applikation
Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This RET antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1012-1042 amino acids from the C-terminal region of human RET.
RET
Reaktivität: Human
WB, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1.79 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper
Hintergrund
RET, a member of the cadherin superfamily, is one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This protein plays a crucial role in neural crest development, and the gene can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations i are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma.